Samsara Welcomes Lara Caimi as President, Worldwide Field Operations
Accomplished Technology Executive to Lead Samsara’s Global Field Operations SAN FRANCISCO–(BUSINESS WIRE)–Samsara Inc. (“Samsara”) (NYSE:…
News
ZoomInfo to Speak at Forrester B2B Summit in Austin
Customers Will Share How ZoomInfo Helped Them Achieve Faster Success with an Efficient Go-To-Market Motion…
New Cloud Security Alliance Survey Finds SaaS Security Has Become a Top Priority for 80% of Organizations
More than half of security executives experienced a SaaS security incident in the past two…
Novan to Provide Corporate Update at its 2023 Annual Meeting of Stockholders
DURHAM, N.C., June 05, 2023 (GLOBE NEWSWIRE) — Novan, Inc. (“the Company” or “Novan”) (Nasdaq:…
Novan to Provide Corporate Update at its 2023 Annual Meeting of Stockholders
DURHAM, N.C., June 05, 2023 (GLOBE NEWSWIRE) — Novan, Inc. (“the Company” or “Novan”) (Nasdaq:…
Shanghai Escugen Biotechnology Co., Ltd., a partner of Levena Biopharma, a Sorrento Company, releases positive results from a first-in-human study of ESG401, a TROP2 Antibody Drug Conjugate in patients with locally advanced/metastatic solid tumors at the ASCO 2023 Meeting
Figure 1 Sorrento Therapeutics, Inc. Figure 2 Sorrento Therapeutics, Inc. Figure 3 Sorrento Therapeutics, Inc….
Shanghai Escugen Biotechnology Co., Ltd., a partner of Levena Biopharma, a Sorrento Company, releases positive results from a first-in-human study of ESG401, a TROP2 Antibody Drug Conjugate in patients with locally advanced/metastatic solid tumors at the ASCO 2023 Meeting
Figure 1 Sorrento Therapeutics, Inc. Figure 2 Sorrento Therapeutics, Inc. Figure 3 Sorrento Therapeutics, Inc….
Lucy Scientific Discovery Announces Proposal to Acquire Pasithea Therapeutics Corp.
VANCOUVER, British Columbia, June 05, 2023 (GLOBE NEWSWIRE) — Lucy Scientific Discovery Inc. (“Lucy” or…
Lucy Scientific Discovery Announces Proposal to Acquire Pasithea Therapeutics Corp.
VANCOUVER, British Columbia, June 05, 2023 (GLOBE NEWSWIRE) — Lucy Scientific Discovery Inc. (“Lucy” or…
T2 Biosystems Announces Submission for FDA Breakthrough Device Designation for Candida Auris Diagnostic Test
Company plans to add multidrug-resistant Candida auris detection to its FDA-cleared T2Candida Panel LEXINGTON, Mass.,…
T2 Biosystems Announces Submission for FDA Breakthrough Device Designation for Candida Auris Diagnostic Test
Company plans to add multidrug-resistant Candida auris detection to its FDA-cleared T2Candida Panel LEXINGTON, Mass.,…
Surrozen Publishes Study in Nature Communications Demonstrating the Promise of a Fzd4 Wnt Antibody in Treating Ischemic Stroke
In a preclinical model of ischemic stroke, systemic delivery of a selective Fzd4 Wnt antibody…
Surrozen Publishes Study in Nature Communications Demonstrating the Promise of a Fzd4 Wnt Antibody in Treating Ischemic Stroke
In a preclinical model of ischemic stroke, systemic delivery of a selective Fzd4 Wnt antibody…
Tarsus to Present at the Jefferies Global Healthcare Conference
IRVINE, Calif., June 05, 2023 (GLOBE NEWSWIRE) — Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission…
Tarsus to Present at the Jefferies Global Healthcare Conference
IRVINE, Calif., June 05, 2023 (GLOBE NEWSWIRE) — Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission…
Ambrx Appoints Jared Kelly as General Counsel
SAN DIEGO, June 05, 2023 (GLOBE NEWSWIRE) — Ambrx Biopharma Inc., or Ambrx (NASDAQ: AMAM),…
Ambrx Appoints Jared Kelly as General Counsel
SAN DIEGO, June 05, 2023 (GLOBE NEWSWIRE) — Ambrx Biopharma Inc., or Ambrx (NASDAQ: AMAM),…
Poster Highlighting Qualigen Therapeutics’ Pan-RAS Inhibitor Platform Presented at American Society of Clinical Oncology (ASCO) 2023 Annual Meeting
Qualigen Therapeutics, Inc. Co-operation between RAS-F series and AMG-510 and MRTX1133 Preclinical Data Show Potential…
Poster Highlighting Qualigen Therapeutics’ Pan-RAS Inhibitor Platform Presented at American Society of Clinical Oncology (ASCO) 2023 Annual Meeting
Qualigen Therapeutics, Inc. Co-operation between RAS-F series and AMG-510 and MRTX1133 Preclinical Data Show Potential…
Morphogenesis, Inc. and CohBar, Inc. Announce Positive Results from Phase 1b Trial of IFx-Hu2.0, a Novel Personalized Cancer Vaccine, in Checkpoint Inhibitor Resistant Advanced Merkel Cell Carcinoma (MCC) and Cutaneous Squamous Cell Carcinoma (cSCC)
IFx-Hu2.0 demonstrated to have a promising safety profile at all 3 dose schedules tested 5…